Anita Bellail
Chief Executive Director HB Therapeutics, Inc.
Anita Bellail, Ph.D. is the Co-Founder and Chief Executive Officer of HB Therapeutics, a biotechnology company advancing proximity-based drug discovery with a focus on molecular glue degraders. Under her leadership, HB Therapeutics is pioneering the development of first-in-class degraders targeting oncoproteins, including a KRAS/CRAF co-degrader program. Dr. Bellail brings more than 20 years of experience in ubiquitin biology and protein degradation, bridging deep scientific expertise with entrepreneurial vision to drive novel therapeutic innovation.
Seminars
Thursday 29th January 2026
Harnessing Novel Molecular Glue Degraders to Target K-Ras Mutants & Overcome Resistance Pathways
9:00 am
- Engaging a novel ligase for targeted degradation to selectively degrade mutant K-Ras while sparing the wild-type protein
- Dual-target effect via co-degradation of Seraph, addressing the major resistance pathway in K-Ras-driven cancers and creating a unique therapeutic opportunity
- Structural insights into ternary complex formation, revealing how the molecular glue stabilizes interactions between the ligase and target proteins, guiding next-generation degrader design
